Claims
- 1. A compound of the formula I:
- 2. The compound according to claim 1 wherein B1 and B2 are hydrogen.
- 3. The compound according to claim 2 wherein X is —(CH2)n and n is 1.
- 4. The compound according to claim 3 wherein R1 is acetyl or hydrogen.
- 5. The compound according to claim 4 wherein the compound is [4S-[4α,7α(S),12bβ]]-7-[[2(R)-acetylthio-3-methyl-1-oxobutyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid, diphenylmethyl ester.
- 6. The compound according to claim 4 wherein the compound is [4S-[4α,7α(S), 12bβ]]-7-[[2(S)-acetylthio-3-methyl-1-oxobutyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid, diphenylmethyl ester.
- 7. The compound according to claim 4 wherein the compound is [4S-[4α,7α(S), 12bβ]]-7-[[3-methyl-1-oxo-2(R)-thiobutyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid, diphenylmethyl ester.
- 8. The compound according to claim 4 wherein the compound is [4S-[4α,7α(S),12bβ]]-7-[[3-methyl-1-oxo-2(S)-thiobutyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid, diphenylmethyl ester.
- 9. The compound according to claim 4 wherein R2 is hydrogen.
- 10. The compound according to claim 9 wherein the compound is [4S-[4α,7α(S), 12bβ]]-7-[[2(R)-acetylthio-3-methyl-1-oxobutyl]amino]-,2,3,4,6,7,8, 2b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid.
- 11. The compound according to claim 9 wherein the compound is [4S-[4α,7α(S), 12bβ]]-7-[[2(S)-acetylthio-3-methyl-1-oxobutyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid.
- 12. The compound according to claim 9 wherein the compound is [4S-[4α,7α(S), 12bβ]]-7-[[3-methyl-1-oxo-2(R)-thiobutyl]amino]-1,2,3,4,6,7,8, 12b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid.
- 13. The compound according to claim 9 wherein the compound is [4S-[4α,7α(S), 12bβ]]-7-[[3-methyl-1-oxo-2(S)-thiobutyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1a][2]benzazepine-4-carboxylic acid.
- 14. A process for the preparation of a compound of the formula I
- 15. A process for the preparation of a compound of the formula II:
- 16. A method of treating a cardiovascular disease condition comprising administering to a patient in need of treatment thereof a therapeutically effective angiotensin converting enzyme and neutral endopeptidase inhibitory amount of a compound according to claim 1.
- 17. The method according to claim 16 wherein the disease condition is hypertension.
- 18. The method according to claim 16 wherein the disease condition is congestive heart failure.
- 19. A pharmaceutical composition comprising one or more compounds as set forth in claim 1 and a pharmaceutically acceptable carrier.
- 20. A method for the preparation of a pharmaceutical composition comprising the step of combining one or more of the compounds as set forth in claim 1 with a pharmaceutically acceptable carrier.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/283,305, filed Apr. 12, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60283305 |
Apr 2001 |
US |